
BioLife Solutions (BLFS) Stock Forecast & Price Target
BioLife Solutions (BLFS) Analyst Ratings
Bulls say
BioLife Solutions Inc. reported a significant year-over-year increase in Cell Processing revenue, reaching $23.0 million, which represents a 28% growth, alongside a 44% increase in evo and Thaw revenue to $2.5 million. Management has raised the revenue guidance for 2025 to a range of $100-103 million, indicating an anticipated overall growth of 22-25%, with Cell Processing specifically projected to grow by 24-26%. Additionally, the expectation of a reduction in net loss and an expansion in adjusted EBITDA margin further supports a positive outlook on the company’s financial trajectory.
Bears say
BioLife Solutions Inc. faces several significant risks, including the potential for lower-than-projected growth of its products and services, difficulties in securing additional customers, and fluctuations in sales due to emerging market dynamics and foreign exchange rates. The company reported a net loss of $15.8 million, equating to a loss of $0.33 per share, which starkly exceeded the anticipated loss of $2.0 million, largely attributed to a hefty $15.5 million in-process R&D expense from the PanTHERA transaction. Such financial underperformance, along with potential dilution risks, raises concerns about the company's future profitability and growth trajectory in the competitive cell and gene therapy market.
This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.
BioLife Solutions (BLFS) Analyst Forecast & Price Prediction
Start investing in BioLife Solutions (BLFS)
Order type
Buy in
Order amount
Est. shares
0 shares